-
公开(公告)号：EP1809318B1
公开(公告)日：2013-06-12
申请号：EP05825013.5
申请日：2005-11-01
发明人： SANGUINETTI, Elizabeth, L. , MARRIOTT, Thomas, B. , LOPANSRI, Jennifer , BLOSCH, Consuelo, Maria
IPC分类号： A61P1/00 , A61K38/26 , C07K14/605
CPC分类号： A61K38/26 , A61B5/4222 , A61K9/0019
摘要： Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
-
公开(公告)号：EP2569001A2
公开(公告)日：2013-03-20
申请号：EP11781220.6
申请日：2011-05-11
发明人： JOELSSON, Bo , CHU, Henry H.
IPC分类号： A61K38/26
CPC分类号： A61K38/26
摘要： Methods are provided for treatment or prophylaxis of liver or kidney dysfunction in individuals experiencing one or more of intestinal failure, short bowel syndrome or parenteral nutrition by the administration of GLP-2 or GLP-2 analogs.
-
3.发明公开Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases 失效结合对受体的新位置的化合物 - 起作用的钙通道，用于治疗神经疾病的治疗中是有效的
公开(公告)号：EP1749522A3
公开(公告)日：2010-10-27
申请号：EP06024225.2
申请日：1994-10-26
发明人： Barmore, Robert M. , Mueller, Alan L. , Van Wagenen, Bradford C. , Delmar, Eric G. , Balandrin, Manuel F. , Moe, Scott T. , Artman, Linda T.
IPC分类号： A61K31/165 , A61K31/404 , A61P9/10 , A61P25/28 , A61P25/04 , C07D209/18 , C07C279/14 , C07C237/22 , C07C233/22 , C07C235/34
CPC分类号： A61K31/135 , A61K31/136 , A61K31/137 , A61K31/138 , A61K31/165 , A61K31/295 , A61K31/381 , A61K31/40 , A61K31/404 , A61K31/4409 , A61K31/4462 , A61K31/4465 , C07C233/22 , C07C235/34 , C07C237/22 , C07C279/14 , C07D209/18 , G01N2800/28
摘要： Method for identifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or useful as a muscle relaxant, analgesic, or adjuvant to general anesthetics. The compounds is active on a receptor-operated calcium channel, including, but not limited to, that present as part of an NMDA receptor-ionophore complex, a calcium-permeable AMPA receptor, or a nicotinic cholinergic receptor, as a noncompetitive antagonist. The method includes identifying a compound which bonds to the receptor-operated calcium channel at the site bound by the arylalkylamines Compound 1, Compound 2 or Compound 3.
-
公开(公告)号：EP1231219B1
公开(公告)日：2010-08-25
申请号：EP01129072.3
申请日：1997-04-11
IPC分类号： C07K14/605 , A61K38/26 , G01N33/68
CPC分类号： C07K14/605 , A61K38/00
-
公开(公告)号：EP2141146A1
公开(公告)日：2010-01-06
申请号：EP09002553.7
申请日：2001-01-24
发明人： Lago, Amparo M. , Callahan, James, Francis , Bhatnagar, Pradip, Kumar , Del Mar, Eric, G. , Bryan, William, M. , Burgess, Joelle, L.
IPC分类号： C07C69/616 , C07C69/738 , C07C211/30 , C07C233/05 , C07C251/48 , C07C255/48 , C07C255/57 , C07D303/22 , A61K31/277 , A61K31/195 , A61K31/216 , A61P19/08 , A61P19/10
CPC分类号： C07D303/22 , C07C69/616 , C07C69/738 , C07C211/30 , C07C233/05 , C07C251/48 , C07C255/57 , C07C255/58 , C07C2602/08 , C07C2602/10
摘要： Novel calcilytic compounds and methods of using them are provided.
摘要翻译： 提供了新的钙溶解化合物及其使用方法。
-
6.发明授权PERIPHERAL NERVOUS SYSTEM SPECIFIC SODIUM CHANNELS, DNA ENCODING THEREFOR, DRUG SCREENING, AND METHODS OF MAKING AND USING THEREOF 无效的钠离子通道专门为外周神经系统，这些代码DNA，主动搜索及其制造方法和使用
公开(公告)号：EP0789575B8
公开(公告)日：2009-01-14
申请号：EP95939723.3
申请日：1995-11-02
IPC分类号： C12N15/12 , C07K14/705 , A61K38/17 , C12Q1/68 , G01N33/68
CPC分类号： C07K14/705 , A61K31/495 , A61K38/00 , C12Q1/6883
-
公开(公告)号：EP1963277A1
公开(公告)日：2008-09-03
申请号：EP06846639.0
申请日：2006-12-15
发明人： HIGGINS, Guy, A. , ISSAC, Methvin , SLASSI, Abdelmalik , XIN, Tao
IPC分类号： C07D233/20 , C07C271/22 , C07C237/06 , C07C311/06 , A61K31/165 , A61K31/18
CPC分类号： C07C311/06 , C07C237/22 , C07C271/22 , C07D233/20
摘要： Compounds of Formula I are useful in the treatment of epilepsy, neuropathic pain, acute and chronic inflammatory pain, migraine, tardive dyskinesia and other related CNS disorders. wherein: A and R1 to R8 are defined in the specification.
-
公开(公告)号：EP1632470A3
公开(公告)日：2007-07-18
申请号：EP05077693.9
申请日：1992-08-21
IPC分类号： C07C211/27 , C07D209/14 , C07C229/38 , C07C217/58
CPC分类号： A61K31/70 , A61K31/13 , A61K31/135 , A61K31/137 , A61K31/165 , A61K31/275 , A61K31/395 , A61K31/40 , A61K31/44 , A61K31/55 , A61K31/715 , A61K38/16 , C07C211/27 , C07C211/29 , C07C211/30 , C07C211/42 , C07C215/52 , C07C217/58 , C07C217/60 , C07C225/16 , C07C229/38 , C07C233/05 , C07C255/58 , C07C2601/14 , C07C2602/08 , C07D209/14 , C07D209/16 , C07D209/18 , C07D213/38 , C07D233/64 , C07K14/705 , G01N33/5008 , G01N33/5011 , G01N33/502 , G01N33/5044 , G01N33/5091 , G01N33/566 , G01N33/567 , G01N33/6872 , G01N2500/10 , G01N2500/20 , G01N2800/04
摘要： Method and composition useful for treating a patient having a disease characterized by an abnormal level of one or more components, the activity of which is regulated or affected by activity of one or more Ca 2+ receptors. Novel compounds useful in these methods and compositions are also provided. The method includes administering to the patient a therapeutically effective amount of a molecule active at one or more Ca 2+ receptors as an agonist or antagonist. Preferably, the molecule is able to act as either a selective agonist or antagonist at a Ca 2+ receptor of one or more but not all cells chosen from the group consisting of parathyroid cells, bone osteoclasts, juxtaglomerular kidney cells, proximal tubule kidney cells, keratinocytes, parafollicular thyroid cells and placental throphoblasts and a pharmaceutically acceptable carrier.
-
公开(公告)号：EP0787122B1
公开(公告)日：2007-04-11
申请号：EP95940547.3
申请日：1995-10-23
发明人： VAN WAGENEN, Bradford, C. , MOE, Scott, T. , BALANDRIN, Manuel, F. , DELMAR, Eric, G. , NEMETH, Edward, F.
IPC分类号： C07C211/27 , C07C211/30 , C07C217/58 , C07C211/28 , A61K31/135
CPC分类号： G01N33/6872 , A61K31/135 , A61K31/137 , C07C211/27 , C07C211/28 , C07C211/30 , C07C217/58 , C07C217/62 , C07C225/16 , C07C317/32 , C07C323/32 , C07D319/18 , G01N33/566 , G01N2500/10 , G01N2800/04
摘要： The present invention features compounds of general formulae a), b), c), able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders by modulating inorganic ion receptor activity. Preferably, the compound can mimic or block the effect of extracellular Ca2+ on a calcium receptor.
-
10.发明公开5-FLUORO-, CHLORO- AND CYANO-PYRIDIN-2-YL-TETRAZOLES AS LIGANDS OF THE METABOTROPIC GLUTAMATE RECEPTOR-5 有权5-氟和氯 - 吡啶-2-基 - 四唑作为代谢型谷氨酸受体5配体
公开(公告)号：EP1713791A1
公开(公告)日：2006-10-25
申请号：EP04813689.9
申请日：2004-12-13
发明人： WENSBO, David, AstraZeneca R & D Headquaters , EDWARDS, Louise , ISAAC, Methvin , MCLEOD, Donald A. , SLASSI, Abdelmalik , XIN, Tao , STORMANN, Thomas M.
IPC分类号： C07D401/04 , C07D213/84 , A61K31/4439 , A61P25/04
CPC分类号： C07D213/84 , C07D401/04
摘要： The present invention relates to new compounds of formula I, wherein Z, Q, X1, X2, R1 and R2, are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
-
-
-
-
-
-
-
-
-
搜索结果
166 条记录 (耗时 0.021 秒)
